Merck & Company, Inc. Press Releases

MRK 
$56.74
*  
1.34
2.31%
Get MRK Alerts
*Delayed - data as of Jul. 31, 2014  -  Find a broker to begin trading MRK now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Merck Announces Second-Quarter 2014 Financial Results
7/29/2014 6:56:00 AM - Business Wire

Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients
7/24/2014 8:30:00 AM - Business Wire

Merck Announces Fourth-Quarter 2014 Dividend
7/23/2014 12:15:00 PM - Business Wire

Merck's HIV Campaign, I Design, Partners with Music Industry Promoter and HIV Advocate Maria Davis and Positive Women's Network - USA to Encourage Women Living with HIV to be "Vocal" about their Treatment
7/17/2014 8:30:00 AM - PR Newswire

Merck Announces Data from Investigational Phase 3 Study on EMEND® (aprepitant) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Undergoing Emetogenic Chemotherapy
6/30/2014 8:00:00 AM - Business Wire

MSD’s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma
6/30/2014 6:00:00 AM - Business Wire

Merck’s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma
6/30/2014 6:00:00 AM - Business Wire

Award-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes to Get to Their Goals
6/26/2014 8:00:00 AM - PR Newswire

Merck to Hold Second-Quarter 2014 Sales and Earnings Conference Call on July 29
6/23/2014 5:00:00 PM - Business Wire

Merck Names Michael J. Holston as Future General Counsel; Will Succeed Bruce N. Kuhlik in July 2015
6/23/2014 8:00:00 AM - Business Wire

Merck Begins Tender Offer to Acquire Idenix
6/20/2014 7:30:00 AM - Business Wire

Merck Launches Global Patient Registry Supporting Expanded Commitment to Real-World Outcomes Research in Type 2 Diabetes
6/13/2014 8:00:00 AM - Business Wire

Health Care Sector Equities Coverage -- Research on Johnson and Johnson, Medicines Co., Merck, and Novo Nordisk
6/13/2014 7:40:00 AM - PR Newswire

Ryan & Maniskas, LLP Announces Investigation of Idenix Pharmaceuticals Inc.
6/10/2014 11:45:00 AM - PR Newswire

IDENIX PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
6/9/2014 1:28:00 PM - Business Wire

Merck to Acquire Idenix
6/9/2014 7:30:00 AM - Business Wire

MSD to Present New Clinical Data on Sitagliptin, Investigational Omarigliptin, and Real-World Data in Patients with Type 2 Diabetes at the 74th Scientific Sessions of the American Diabetes Association
6/6/2014 8:00:00 AM - Business Wire

Merck to Present New Clinical Data on JANUVIA® (Sitagliptin), Investigational Omarigliptin, and Real-World Data in Patients with Type 2 Diabetes at the 74th Scientific Sessions of the American Diabetes Association
6/6/2014 8:00:00 AM - Business Wire

First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily Dosing Regimen of ISENTRESS® (raltegravir)
6/5/2014 5:00:00 PM - Business Wire

First Presentation of Data for Pembrolizumab, Merck’s Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, Advanced Non-Small Cell Lung Cancer (NSCLC) at ASCO 2014
6/2/2014 7:30:00 AM - Business Wire

Data on Merck’s Pembrolizumab from Largest Study to Date of Investigational Anti-PD-1 Antibody in Advanced Melanoma Highlighted at ASCO 2014
6/2/2014 7:30:00 AM - Business Wire

First Presentation of Early Data for Pembrolizumab (MK-3475), Merck’s Investigational Anti-PD-1 Antibody, in Advanced Head and Neck Cancer at ASCO 2014
6/1/2014 9:23:00 AM - Business Wire

EMD Serono to Release New Pipeline Data at ASCO 2014 from Early-Stage Investigational Compounds in Difficult-to-Treat Cancers
5/29/2014 2:30:00 AM - PR Newswire

Merck Announces Third-Quarter 2014 Dividend
5/27/2014 12:21:00 PM - Business Wire

Technical Data on Active Stocks -- Research on Freeport-McMoRan Copper & Gold, SLM Corp., Brocade Communications Systems, and Merck & Co.
5/20/2014 9:20:00 AM - PR Newswire